Skip to main content
SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD logo

SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD — Investor Relations & Filings

Ticker · 000078 ISIN · CNE000000X95 LEI · 300300J4GCOV7CYQTB51 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,614 across all filing types
Latest filing 2025-06-06 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 000078

About SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD

https://www.neptunusbio.com

Shenzhen Neptunus Bioengineering Co., Ltd. is a comprehensive healthcare enterprise focused on the research, development, manufacturing, and distribution of pharmaceutical products. The company operates across the entire industry value chain, including the production of chemical drugs, biological preparations, and traditional Chinese medicines. Its portfolio extends to medical devices and health supplements. A significant component of its operations involves a large-scale pharmaceutical distribution network and a nationwide retail pharmacy chain. The company emphasizes innovation in biotechnology and maintains modern production facilities to support its diverse product lines. By integrating R&D with a robust logistics and retail infrastructure, it provides a wide range of healthcare solutions to medical institutions and consumers.

Recent filings

Filing Released Lang Actions
监事会关于第九届监事会第二十次会议相关事项的意见
Regulatory Filings Classification · 95% confidence The document is a short statement from the supervisory board of Shenzhen Haiwang Bioengineering Co., Ltd. regarding the termination of a specific share issuance plan for 2024. It contains opinions and approvals related to corporate governance and decision-making but does not include financial statements or detailed financial data. The document length is only 389 characters, indicating it is a brief announcement rather than a full report. It is not an annual or interim report, audit report, or earnings release. It relates to a capital issuance matter but is an opinion from the supervisory board rather than a direct capital/financing update or share issue announcement. Given the nature and length, it fits best under Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2025-06-06 Chinese
第九届监事会第二十次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of resolutions passed at a supervisory board meeting of Shenzhen Haiwang Bioengineering Co., Ltd. It details the meeting date, voting results, and references other announcements for more details. The document is short (748 characters) and does not contain financial statements or detailed financial data. It is an official announcement of board meeting decisions rather than a full management report or financial report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for regulatory announcements that do not fit other specific categories.
2025-06-06 Chinese
第九届董事局第二十四次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at a board of directors meeting of Shenzhen Haier Bioengineering Co., Ltd. It details the meeting date, attendance, and voting results on specific agenda items related to termination of a stock issuance and related agreements. The document does not contain financial statements or detailed financial data, nor is it a report or presentation. It is an announcement of board decisions, specifically resolutions passed by the board. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and it is not a report publication announcement or regulatory filing. Hence, the classification is MANG with high confidence.
2025-06-06 Chinese
关于终止控制权变更及向特定对象发行股票事项的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from Shenzhen Haiwang Bioengineering Co., Ltd. regarding the termination of a planned change in control and a specific share issuance to designated investors. It details the cancellation of agreements related to share transfer and subscription, the impact on the company, and the approval process by the board, independent directors, and supervisory board. The document does not contain financial statements or detailed financial data but rather reports on corporate actions and decisions related to capital structure and control changes. It is not a full financial report, earnings release, or management discussion. It is a formal announcement about the termination of a capital raising and control change transaction, which fits the category of Capital/Financing Update (CAP). The document length is under 5,000 characters but contains substantive content about financing activities, not merely a report publication announcement or regulatory filing. Therefore, the appropriate classification is CAP with high confidence.
2025-06-06 Chinese
关于为控股子公司提供担保实施情况的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement about the company's provision of guarantees for its subsidiaries' financing activities. It includes specifics about guarantee amounts, counterparties, contract terms, and cumulative guarantee exposure. The content is focused on the company's capital and financing arrangements related to guarantees for credit facilities. There is no indication that this is a full financial report, audit report, or regulatory certification. The document is not a brief announcement of a report publication but a substantive disclosure about financing guarantees. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length (4041 characters) is sufficient to provide detailed information rather than a mere announcement.
2025-05-20 Chinese
关于2024年度会计师事务所履职情况评估报告
Audit Report / Information Classification · 95% confidence The document is an evaluation report on the performance of the external audit firm (致同会计师事务所) for the fiscal year 2024. It details the auditor's qualifications, independence, audit procedures, and overall assessment of their work related to the company's financial statements and internal controls. The document does not contain the actual financial statements or audit opinions themselves but rather an assessment of the auditor's performance and compliance with auditing standards. This fits the definition of an Audit Report / Information (AR), which includes standalone audit reports and evaluations related to auditing activities but excludes full annual reports. The document length is 1786 characters, which is consistent with a detailed report rather than a brief announcement. Therefore, the appropriate classification is AR with high confidence. FY 2024
2025-04-28 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.